跳至主要内容
临床试验/NCT00409799
NCT00409799已完成2 期

A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.

Kuros Biosurgery AG45 个研究点 分布在 9 个国家目标入组 208 人开始时间: 2006年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
208
试验地点
45
主要终点
Radiographic Images

研究概览

简要总结

For certain tibial plateau fractures the bone is compressed due to the force acting on the tibia during the accident. The void provoked by the compression of the bone is filled with an appropriate filling material and the fracture is fixated. I 0401 is a new bone graft substitute that has shown capacities to promote bone-healing. This study will test the safety and efficacy of I 0401 in the treatment of patients with tibial plateau fractures requiring grafting.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Radiological evidence of a tibial plateau fracture requiring grafting
  • Females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening).

排除标准

  • Concomitant ipsilateral fractures of the limb other than the fracture of the tibial plateau.
  • Active or past history of malignant tumor.
  • Evidence of systemic or localized infection at time of surgery.
  • Pregnant or lactating females.

研究组 & 干预措施

1

Experimental

Experimental - high dose

干预措施: I-0401 (a new bone graft substitute) (Drug)

2

Experimental

Experimental - low dose

干预措施: I-0401 (a new bone graft substitute) (Drug)

3

Active Comparator

Autograft

干预措施: I-0401 (a new bone graft substitute) (Drug)

结局指标

主要结局

Radiographic Images

时间窗: All Follow-Up Visits

次要结局

  • Clinical assessments of the fracture site(All Follow-Up Visits)
  • Blood parameters(All Follow-Up Visits)
  • Vital signs(At several Follow-Up visits)
  • Questionnaires of Life(All Follow-Up Visits)
  • Pharmacoeconomic evaluation(All Follow-Up Visits)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (45)

Loading locations...

相似试验